Campus alert status is yellow: For the latest UMMS campus alert status, news and resources, visit umassmed.edu/coronavirus

Search Close Search

Print

2021 RESEARCH

- Archives -

Chan Zuckerberg Initiative funds atomic-level imaging research in Grigorieff lab at UMMS

Chan Zuckerberg Initiative funds atomic-level imaging research in Grigorieff lab at UMMS

Nikolaus Grigorieff, PhD, and Bronwyn Lucas, PhD, have received a $1.3 million grant from the Chan Zuckerberg Initiative to develop new computational and data collection tools for locating specific molecules with near-atomic accuracy within cells using cryo-EM imaging technology.

BRIDGE grants support research into rare Sialidosis disease and patch to prevent pressure ulcers

BRIDGE grants support research into rare Sialidosis disease and patch to prevent pressure ulcers

Heather Gray-Edwards, PhD, DVM; Miguel Sena-Esteves, PhD; and Raymond Dunn, MD, are the recipients of the Office of Business Development & Innovation 2021 BRIDGE Fund grants.

UMass Medical School to participate in trial of Pfizer COVID-19 booster vaccine

UMass Medical School to participate in trial of Pfizer COVID-19 booster vaccine

UMass Medical School intends to start enrolling by the end of June approximately 100 participants from its initial Pfizer trial in a study of a vaccine booster. The booster would be given roughly six months after participants received their second shot of the original vaccine.

UMMS research identifies potential antiviral compound for COVID-19, flu, other viral infection

UMMS research identifies potential antiviral compound for COVID-19, flu, other viral infection

Katherine A. Fitzgerald, PhD; Fiachra Humphries, PhD; and Liraz Galia, PhD, working with the British-based pharmaceutical company GlaxoSmithKline, have identified a novel molecule capable of stimulating the innate immune system against SARS-CoV-2 virus.

UMass Medical School cardiology experts report link between mild heart problem, COVID vaccine

UMass Medical School cardiology experts report link between mild heart problem, COVID vaccine

Researchers at UMass Medical School have reported on a case of mild heart inflammation in a young male received mRNA COVID-19 vaccine.

Moderna’s TeenCOVE study of COVID-19 vaccine, with UMMS participants, meets primary endpoints

Moderna’s TeenCOVE study of COVID-19 vaccine, with UMMS participants, meets primary endpoints

UMass Medical School is a study site for the Phase II/III study of Moderna’s COVID-19 vaccine in adolescents between ages 12 and 17, called TeenCOVE.

UMMS helps gather data leading to eased CDC guidelines for fully vaccinated individuals

UMMS helps gather data leading to eased CDC guidelines for fully vaccinated individuals

Preliminary data published this month from a surveillance project conducted at UMass Medical School evaluating the effectiveness of two COVID vaccines played a critical role in new guidelines by the CDC that no longer require fully vaccinated individuals to wear masks.

Dietary study finds more produce, less salt positively impact markers of heart health

Dietary study finds more produce, less salt positively impact markers of heart health

A new study co-authored by UMass Medical School preventive cardiology expert Lara Kovell, MD, finds that diets with lots of fruits and vegetables and not too much salt positively impact three markers that can predict or be evidence of existing cardiovascular disease.

RADx initiative highlighted during congressional visit to NIH campus

RADx initiative highlighted during congressional visit to NIH campus

United States senators visited the National Institutes of Health at its Bethesda campus on May 17 for a tour of its Vaccine Research Center and discussion of COVID-19 initiatives, including the National Institutes of Health Rapid Acceleration of Diagnostics initiative, or RADx.

Early data from TeenCOVE study shows Moderna COVID-19 vaccine effective, safe for ages 12-17

Early data from TeenCOVE study shows Moderna COVID-19 vaccine effective, safe for ages 12-17

Initial analysis of the Phase II/III TeenCOVE study of Moderna’s mRNA vaccine, in which UMass Medical School is participating, showed vaccine efficacy against COVID-19 of 96 percent, the company reported.

Showing 1-10 of 47 items
of 5